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Abstract
The synthesis and characterization of a number of organometallic ruthenium(II) complexes
containing a series of bidentate thiosemicarbazone ligands derived from piperonal is reported. The
structure of compounds have been confirmed by spectroscopic analysis (IR and NMR) as well as
X-ray crystallographic analysis of [(η6-p-cymene)Ru(pPhTSC)Cl]Cl (4) (pPhTSC is piperonal-
N(4)-phenylthiosemicarbazone). The interaction of the complexes ([(η6-p-
cymene)Ru(pEtTSC)Cl]Cl) (3) (pEtTSC is piperonal-N(4)-ethylthiosemicarbazone) and 4 with
calf thymus DNA, human serum albumin (HSA) and pBR322 plasmid DNA were studied by
spectroscopic, gel electrophoresis and hydrodynamic methods. The apparent binding constant for
the interaction with DNA was determined to be 3.97 × 103 M−1 and 4.07 × 103 M−1 at 293 K for 3
and 4 respectively. The complexes bind strongly to HSA with binding constants of 2.94 × 104 M−1
and 12.2 × 104 M−1 at 296 K for 3 and 4 respectively. The in vitro anticancer activity of 3 and 4
has been evaluated against two human colon cancer cell line (HCT-116 and Caco-2) with IC50
values in the range 26 – 150 µM. Both 3 and 4 show good activity as a catalytic inhibitor of
human topoisomerase II at concentrations as low as 20 µM. The proficiency of 3 and 4 to act as
antibacterial agents was also evaluated against six pathogenic bacterial strains with the best
activity seen against Gram-positive strains.
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1 Introduction
Medicinal inorganic chemistry is a discipline of growing importance and the rich diversity
of coordination chemistry provides opportunities for the design of new pharmaceuticals.
More recently organometallic complexes, initiated by the metallocenes, have been studied
intensively (Fig. 1). Titanocene dichloride (I), for instance was in clinical trials but it was
difficult to formulate [1]. Ferrocenyl analogues show excellent cytotoxicities in vitro and
inhibit the development of tumours in vivo [2]. Other metals have been used as the central
metal atom. Organometallic ruthenium (Ru), particularly the half-sandwich complexes like
II and III, are emerging as a very promising class of anti-tumour compounds. The geometry
of these complexes provide a good scaffold for building new molecules by changing the
coordinated arene, the chelated ligand and the chloride group. So compound II, RM175,
developed by Sadler et.al. shows anti-cancer activity including activity against cisplatin-
resistant cell lines [3]. Complexes like III, the so-called RAPTA compounds from the
Dyson group, have low in vitro cytotoxicity but show in vivo antimetastic behavior [4].
A modern twist to the idea of combining organometallic and biological components has led
to the development of new and promising anticancer drugs. An example of this synergy
obtained by modification of a biologically active organometallic fragment with a known
drug is the class of compounds known as the ferrocifens developed by Jaouen [5–8]. for
adjuvant treatment of hormone-dependent cancers. The compounds are created by
appending SERMs (selective estrogen receptor modulators) to a ferrocenyl unit. In
particular, hydroxyl ferrocifen (IV) shows anti-proliferative effects on both ER(+) and
ER(−) breast cancer cell cultures, in contrast to the parent tamoxifen. This approach has also
been used to create ferroquine – a compound in Phase II clinical trials made by the linking
of ferrocene to the anti-malarial chloroquine [9,10].
It has been noted that this strategy of tethering a known drug to a biologically active moiety
can endow the drug with new biological properties [11]. In our research group we utilize this
strategy by combining the Ru-arene fragment to thiosemicarbazones [12].
Thiosemicarbazones are of considerable pharmacological interest since a number of
derivatives have shown a broad spectrum of chemotherapeutic properties. The wide range of
biological activities possessed by substituted thiosemicarbazones includes cytotoxic,
antitumor [13], antibacterial [14], and antiviral [15] properties. The biological properties of
the ligands can be modified and in fact enhanced, by the linkage to metal ions [16–18]. In
this paper, we report on a study (synthesis, characterization, structure and biological
activity) of a series of half-sandwich organometallic ruthenium complexes containing
piperonal thiosemicarbazones as the chelating ligand.
2 Experimental
2.1 Material and Methods
Analytical or reagent grade chemicals were used throughout. All the chemicals including
solvents were obtained from Sigma-Aldrich or other commercial vendors and used as
received. Microanalyses (C, H, N) were performed by Columbia Analytical, (Tucson, AZ).
Proton and carbon NMR spectra were recorded in dimethylsulfoxide-d6 on a Varian
Mercury 300 spectrometer operating at room temperature. The residual 1H and 13C present
in DMSO-d6 (2.50 and 39.51 ppm respectively) were used as internal references. The
splitting of proton resonances in the reported 1H NMR spectra is defined as s = singlet, d =
doublet, t = triplet, q = quartet and wm = wide multiplet. IR spectra in the range 4000 − 500
cm−1 were obtained using KBr pellets or using the ATR accessory on a Nicolet 6700 FTIR
spectrophotometer. Cyclic voltammetric (CV) data were collected on a Bioanalytical
Systems Inc. Episilon workstation on a C3 cell stand at 296 K. CH2Cl2 solutions (1 × 10−3
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M) containing 0.1 M tetrabutylammonium hexafluorophosphate were saturated with
nitrogen for 15 minutes prior to each run. A blanket of nitrogen gas was maintained
throughout the measurements. The measurements were carried out with a three-electrode
system consisting of a platinum working electrode, a platinum wire auxiliary electrode and a
Ag-AgCl reference electrode. Ferrocene was used as an internal standard. The working
electrode was polished before each experiment with alumina slurry. Fluorescence spectra
were recorded on a Varian Cary Eclipse spectrophotometer. Melting points (triplicate
measurements) were determined in open capillaries on a Buchi B-545 melting point
apparatus and are uncorrected.
2.2 Syntheses
The ligands, piperonal thiosemicarbazone (pHTSC), piperonal-N(4)-
methylthiosemicarbazone (pMeTSC), piperonal-N(4)-ethylthiosemicarbazone (pEtTSC) and
piperonal-N(4)-phenylthiosemicarbazone (pPhTSC), were synthesized as follows:
Equimolar amounts piperonal and the appropriate N(4) alkyl-substituted thiosemicarbazide
were suspended in 80 mL of absolute anhydrous ethanol containing a few drops of glacial
acetic acid. The reaction mixture was heated at reflux for 3 to 4 h and a pale yellow
suspension resulted. The reaction mixture was cooled and filtered through a glass-sintered
crucible. The pale yellow solid which was obtained was washed thoroughly with ethanol
followed by ether and air-dried on the vacuum line.
pHTSC—Yield 80% of an off-white solid. Analysis - Calc for C9H9N3O2S: C, 48.42; H,
4.06; N, 18.82. Found: C, 48.40; H, 4.02; N, 18.67. m.p.189 °C. IR (cm−1): ν (NH2, NH)
3427, 3252, 3153; ν (C=N) 1592; ν (C=S) 1260, 838. 1H NMR (300.08 MHz, DMSO-d6): δ
= 6.04 (2H, s, H1), 7.63 (1H, s, H3), 7.04 (1H, d J = 8.4 Hz, H5), 6.89 (1H, d J = 7.8 Hz,
H6), 7.92 (1H, s, H8), 8.01 (1H, s, NbH), 8.04 (1H, s, NbH), 11.3 (1H, s, NaH). 13C NMR
(75.463 MHz, DMSO-d6); δ = 102.01 (C1), 105.97 (C6), 108.81 (C3), 124.55 (C5), 129.42
(C4), 142.68 (C8), 148.70 (C2), 149.54 (C7), 178.30 (C9)
pMeTSC—Yield 96% of a pale-yellow solid. Analysis - Calc for C10H11N3O2S: C, 50.62;
H, 4.67; N, 17.71. Found: C, 50.62; H, 4.62; N, 17.50. m.p. 209 °C. IR (cm−1): ν (NH2, NH)
3344, 3152; ν (C=N) 1590; ν (C=S) 1283, 828. 1H NMR (300.08 MHz, DMSO-d6): δ = 6.07
(2H, s, H1), 7.66 (1H, s, H3), 7.07 (1H, d J = 8.1 Hz, H5), 6.91 (1H, d J = 7.8 Hz, H6), 8.51
(1H, s, H8), 7.94 (1H, s, NbH), 11.38 (1H, s, NaH), 3.00 (3H, t, Nb-CH3). 13C NMR (75.463
MHz, DMSO-d6); δ = 30.78 (Nb-CH3), 101.47 (C1), 105.15 (C6), 108.19 (C3), 123.76 (C5),
128.88 (C4), 141.38 (C8), 148.82 (C2), 148.06 (C7), 177.51 (C9).
pEtTSC—Yield 84% of a pale-yellow solid. Analysis - Calc for C11H13N3O2S: C, 52.57;
H, 5.21; N, 16.72. Found: C, 52.66; H, 5.06; N, 16.58. m.p. 169 °C. IR (cm−1): ν (NH2, NH)
3375, 3143; ν (C=N) 1589; ν (C=S) 1255, 832. 1H NMR (300.08 MHz, DMSO-d6): δ = 6.07
(2H, s, H1), 7.66 (1H, s, H3), 7.07 (1H, d J = 8.1 Hz, H5), 6.92 (1H, d J = 7.8 Hz, H6), 8.56
(1H, s, H8), 7.94 (1H, s, NbH), 11.32 (1H, s, NaH), 3.58 (2H, q, Nb-CH2), 1.14 (3H, t, Nb-
CH2-CH3). 13C NMR (75.463 MHz, DMSO-d6); δ = 14.72 (Nb-CH2-CH3), 38.22 (Nb-CH2-
CH3), 101.47 (C1), 105.23 (C6), 108.19 (C3), 123.78 (C5), 128.84 (C4), 141.50 (C8),
148.83 (C2), 148.05 (C7), 176.46 (C9).
pPhTSC—Yield 94% of a light-yellow solid. Analysis - Calc for C15H13N3O2S: C, 60.18;
H, 4.38; N, 14.04. Found: C, 60.21; H, 4.50; N, 13.95. m.p. 189 °C. IR (cm−1): ν (NH2, NH)
3353, 3134; ν (C=N) 1597; ν (C=S) 1253, 869. 1H NMR (300.08 MHz, DMSO-d6): δ = 6.08
(2H, s, H1), 7.85 (1H, s, H3), 7.55 (1H, d J = 14 Hz, H5), 7.38 (1H, d J = 15 Hz, H6), 8.07
(1H, s, H8), 10.11 (1H, s, NbH), 11.74 (1H, s, NaH), 6.93 – 7.25 (5H, m, Nb-C6H5). 13C
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NMR (75.463 MHz, DMSO-d6); δ = 101.50 (C1), 105.67 (C6), 108.18 (C3), 142.67 (C8),
149.09 (C2), 148.10 (C7), 175.78 (C9).
2.2.1 Metal complexes—The starting metal compound, [(η6- p -cymene)RuCl2]2, was
synthesized as described in the literature [19]. The metal complexes were synthesized using
a common procedure: The starting ruthenium dimer was dissolved in 15 mL of
dichloromethane and the red solution degassed with argon for 15 minutes. Under a flow of
argon, two equivalents of the solid thiosemicarbazone were added and the orange-red
mixture stirred for 2 to 3 h at room temperature. The volume of the reaction mixture was
reduced to ~ 2 mL and ether (10 to 20 mL) was added. The orange-yellow suspension that
resulted was filtered and the solid washed with ether and dried at the vacuum line. The
orange-red solid may be crystallized from dichloromethane and ether. The solids from the
reactions involving pHTSC (1) and pMeTSC (2) appeared hygroscopic and were difficult to
handle. The hexafluorophosphate salts of these ligands as well as pPhTSC could be
synthesized by incorporating NH4PF6 (2.5 equiv) at the start of the reaction. These
complexes were easier to handle but the elemental analyses (for carbon) were outside the
range that is normally acceptable (see Supplemental Information).
[(η6-p-cymene)Ru(pHTSC)Cl]Cl.H2O (1): Orange solid; “static”. Yield: (98%). Analysis;
Calc for C19H25Cl2N3O3SRu: C, 41.61; H, 4.78; N, 7.66. Found: C, 41.64; H, 4.07; N, 7.49.
IR (cm−1): ν (NH2, NH) 3258 (broad, weak); ν (C=N) 1594; ν (C=S) 1266, 803. 1H NMR
(300.08 MHz, DMSO-d6): δ = 6.06 (2H, s, H1), 7.65 (1H, s, H3), 7.07 (1H, d J = 8.4 Hz,
H5), 6.90 (1H, d J = 7.8 Hz, H6), 7.94 (1H, s, H8), 8.04 (1H, s, NbH), 8.13 (1H, s, NbH),
11.32 (1H, s, NaH), 5.80 (m, p-cymene ring), 2.83 (1H, wm, CH(CH3)2), 2.08 (3H, s, CH3-
cymene ring), 1.18 (d, CH(CH3)2). 13C NMR (75.463 MHz, DMSO-d6); δ = 102.08 (C1),
105.99 (C6), 108.83 (C3), 124.56 (C5), 129.45 (C4), 142.62(C8), 148.71 (C2), 149.53 (C7),
178.32 (C9), 86.12 – 107.02 (C6H4), 18.55 (CH3-C6H4), 22.18 (CH(CH3)2), 30.65
(CH(CH3)2).
[(η6-p-cymene)Ru(pMeTSC)Cl]Cl-H2O (2): Hygroscopic orange-red solid. Yield: (40%).
Analysis; Calc for C20H27Cl2N3O3SRu: C, 42.78; H, 4.85; N, 7.48. Found: C, 43.00; H,
4.57; N, 7.39. IR (cm−1): ν (NH2, NH) 3384(b,w), 3258 (b,w); ν (C=N) 1594; ν (C=S) 1266,
803. : 1H NMR (300.08 MHz, DMSO-d6): δ = 6.06 (2H, s, H1), 7.62 (1H, s, H3), 7.09 (1H,
d J = 8.1 Hz, H5), 6.94 (1H, d J = 7.8 Hz, H6), 8.46 (1H, s, H8), 7.96 (1H, s, NbH), 11.31
(1H, s, NaH), 3.02 (3H, t, Nb-CH3), 5.80 (m, p-cymene ring), 2.84 (1H, wm, CH(CH3)2),
2.10 (3H, s, CH3-cymene ring), 1.13 – 1.25 (m, CH(CH3)2). 13C NMR (75.463 MHz,
DMSO-d6); δ = 30.69 (Nb-CH3), 102.17 (C1), 105.85 (C6), 108.86 (C3), 124.48 (C5),
129.61(C4), 142.09 (C8), 149.53(C2), 148.78 (C7), 178.23 (C9), 86.12 – 107.07 (C6H4),
18.61 (CH3-C6H4), 22.21 (CH(CH3)2), 31.46 (CH(CH3)2).
[(η6-p-cymene)Ru(pEtTSC)Cl]Cl (3): Orange-yellow solid. Yield: (73%). Analysis; Calc
for C21H27Cl2N3O2SRu: C, 45.24; H, 4.88; N, 7.46. Found: C, 45.17; H, 4.48; N, 7.46. m.p.
156 °C (char). IR (cm−1): ν (NH2, NH) 3197 (b,w); ν (C=N) 1594; ν (C=S) 1267, 799. 1H
NMR (300.08 MHz, DMSO-d6): δ = 11.33 (1H, s, NaH), 8.58 (1H, s, H8), 7.96 (1H, s,
NbH), 7.66 (1H, s, H3), 7.08 (1H, d, H5), 6.96 (1H, d, H6), 6.08 (2H, s, H1), 5.82 (4H, m, p-
cymene ring), 3.58 (2H, m, Nb-CH2), 2.84 (1H, wm, CH(CH3)2), 2.09 (3H, s, CH3-cymene
ring), 1.14 – 1.18 (m, Nb-CH2-CH3) and CH(CH3)2). 13C NMR (75.463 MHz, DMSO-d6);
δ = 14.71 (Nb-CH2-CH3), 38.19 (Nb-CH2-CH3), 101.46 (C1), 105.23 (C6), 108.20 (C3),
123.78 (C5), 128.83 (C4), 141.47 (C8), 148.81 (C2), 148.04 (C7), 176.43 (C9), 85.52 –
106.35 (C6H4), 17.89 (CH3-C6H4), 21.52 (CH(CH3)2), 29.99 (CH(CH3)2)
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[(η6-p-cymene)Ru(pPhTSC)Cl]Cl (4): Orange-yellow solid. Yield: (79%). Crystals
suitable for X-ray analysis were grown by slow diffusion of ether into a concentrated
dichloromethane solution. Analysis; Calc for C25H27Cl2N3O2SRu: C, 49.59; H, 4.49; N,
6.94. Found: C, 49.13; H, 4.14; N, 6.87. m.p. 174 °C (charring). IR (cm−1): ν (NH2, NH)
3188 (broad, weak); ν (C=N) 1577; ν (C=S) 1266, 822. 1H NMR (300.08 MHz, DMSO-d6):
δ = 11.71 (1H, s, NaH), 10.09 (1H, s, NbH ), 8.05 (1H, s, H8), 7.83 (1H, s, H3), 7.52 (1H, d,
H5), 7.34 (1H, d, H6), 7.12 – 7.21 (m, C6H5), 6.07 (2H, s, H1), 5.79 (m, p-cymene ring),
2.72 (1H, wm, CH(CH3)2), 2.07 (3H, s, CH3-cymene ring), 1.18 (6H, d, CH(CH3)2). 13C
NMR (75.463 MHz, DMSO-d6); δ = 101.47 (C1), 105.59 (C6), 106.33 (C3), 123.78 (C5),
128.84 (C4), 142.65 (C8), 149.07 (C2), 148.08 (C7), 175.75 (C9), 85.52 – 106.35 (C6H4),
17.88 (CH3-C6H4), 21.51 (CH(CH3)2), 29.99 (CH(CH3)2).
2.3 X-ray crystallography
X-ray crystallographic data were collected at 296 (±1) K on a Bruker APEX CCD
diffractometer with Mo Kα radiation (λ = 0.71073 Å) and a detector-to-crystal distance of
4.94 cm. Data collection was optimized utilizing the APEX 2 software [20] with 0.5°
rotation between frames and an exposure time of 10 s per frame. The structures were solved
by direct methods and refined using SHELXTL 6.10 [20]. Data integration, correction for
Lorentz and polarization effects, and final cell refinement was performed using
SAINTPLUS, and corrected for absorption using SADABS. All non-hydrogen atoms were
refined anisotropically and hydrogen atoms placed in calculated positions. Crystallographic
data and data collection parameters are listed in Table 1. A complete list of bond lengths and
angles may be found in the Supporting Information.
2.4 DNA-interaction studies
All the experiments involving the interaction of the complexes with DNA were carried out
in TRIS buffer (5 mM Tris, 50 mM NaCl, pH 7.20). Stock solutions of ct-DNA was
prepared by dissolving commercial nucleic acids in buffer and stored at 4 °C for 24 h to
attain homogeneity. After dilutions DNA concentration per nucleotide phosphate was
determined spectrophotometrically using the molar absorption coefficient of 6600 M−1 cm−1
at 260 nm [21]. A solution of ct-DNA in the buffer gave a ratio of UV absorbance at 260
and 280 nm of ≥ 1.8 indicating that the DNA was sufficiently free from protein
contamination [22]. The DNA stock solutions were stored at 4 °C and used within 4 days
after their preparation. Doubly purified water used in all experiment was from a Milli-Q
system.
2.4.1 Viscosity measurements—Viscosity studies were done using a Cannon-Manning
semi micro-dilution viscometer (type 75, Cannon Instruments Co., State College, PA, USA)
immersed vertically in a thermostatted water bath maintained at 31.0 ± 0.1 °C. The viscosity
for DNA was measured in the presence and absence of the metal complexes. The DNA
concentration was maintained at 100 µM, while the complex concentration was varied from
0 – 60 µM. Data are presented as (η/η0)1/3 versus 1/R, where R = [DNA]/[complex] and η is
the viscosity of DNA in the presence of the complex and η0 is the relative viscosity of DNA
alone. Relative viscosity values were calculated from the observed flow time of DNA
solution (t) and corrected for the flow time of buffer alone (t0), using the expression η0 = (t -
t0)/t0. Flow time was measured with a digital stopwatch and each sample was measured
three times and an average flow time was used.
2.4.2 Ethidium bromide and Hoechst 33258 displacement experiments—In the
ethidium bromide (EB) fluorescence displacement experiment, 3 mL of a solution that is 10
µM DNA and 0.33 µM EB (saturated binding levels) [23], in TRIS buffer was titrated with
concentrated solutions of the complexes producing the solutions with various mole ratios of
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complex to ct-DNA. After each addition the solution was stirred at the appropriate
temperature for 5 minutes before measurement. The fluorescence spectra of the solution
were obtained by exciting at 520 nm and measuring the emission spectra from 530 to 700
nm using 5 nm slits. Temperature was controlled using a single-cell Peltier accessory. The
procedure was the same for the Hoechst 33258 reactions using the following conditions:
working solutions were 20 µM DNA and 2 µM Hoechst 33258; λex = 338 nm and λem = 400
to 550 nm (with λmax = 464 nm).
2.4.3 Chemical nuclease activity—The DNA unwinding and cleavage ability of the
complexes was evaluated by agarose gel electrophoresis of supercoiled pBR322 DNA. The
experiments were done in the dark or with exposure to long-radiation UV light. Samples of
pBR322 DNA (0.1 µg/µL) were incubated with the complexes (in concentration ranging
from 10 to 300 µM) in TRIS buffer (50 mM Tris, 18 mM NaCl, pH 8.2) at room
temperature for 1 h in the dark or subjected to 365 nm light. Samples containing sodium
formate (400 mM), potassium iodide (400 mM) and sodium azide (100 mM) were included
in the experiments. The reactions were quenched by addition of 3 µL of loading buffer
(0.25% bromophenol blue and 15% Ficoll in water). Samples of the reaction mixtures were
loaded onto a 1% agarose gel in TBE buffer (89 mM Tris, 89 mM boric acid, 2 mM EDTA,
pH 8.2). The gels were subjected to electrophoresis for 1 h at 70 V, followed by staining
with 0.5 µg/mL ethidium bromide for 30 min. The bands on the gel were visualized under
UV light and photographed using a GEL Logic 440 Imaging System with a Kodak
Molecular Imaging Software.
2.5 Activity against topoisomerase II
The capability of the ruthenium complexes to affect topoisomerase II activity was analyzed
using gel electrophoresis. The reaction mixture was a total of 20 µL TRIS buffer (50 mM
Tris, 18 mM NaCl, pH 7.2) was used as the reaction buffer for the complexes. The
“complete buffer” was made fresh daily by adding equal volumes of 10x Topo II Assay
Buffer A (0.5 M Tris-HCl (pH 8), 1.50 M NaCl, 100 mM MgCl2, 5 mM dithiothreitol and
300 µg BSA/mL) to the 10x ATP Buffer B (20 mM ATP in water) and was used at 1/5
volume. The metal complexes were added to yield varying concentrations (20 µM, 50 µM,
100 µM, and 300 µM) from a 3 mM stock solution made fresh in a 1:1 solution of DMSO
and TRIS buffer. Etoposide used as a control poison was added from a 10 mM stock
solution in DMSO to create a 1 mM concentration in the reaction. Also a control lane, in
which DMSO was added to DNA at the highest concentration it appears in a single reaction,
was included. DNA (pHOT-1) was used at a concentration of 12.5 ng/µl. Human
topoisomerase IIα (3 units, 1.5 µl) was added and the reactions were immediately transferred
from the ice bath to a 37 °C hot water bath for 30 min. The reactions were terminated by
adding 1/10 volume of 10% sodium dodecyl sulphate. Proteinase K was added at a
concentration of 50 µg/ml. The reactions were incubated in the hot water bath for an
additional 15 min. 1/10 volume of 10x gel loading buffer was added and the reactions
removed from the water bath. They were cleaned up via a CIA extraction. An equal volume
of CIA (chloroform: isoamyl alcohol 24:1) was added, the mixture vortexed and then briefly
centrifuged. The upper blue layer was split in half and placed into corresponding wells of
two 1% agarose gels in TRIS-Borate-EDTA buffer (TBE). One gel contained 0.2 µg/ml
ethidium bromide. The gels were run at 70 V for 2 h in TBE. The EB gel was run with TBE
containing 0.5 µg/ml ethidium bromide. This gel was then de-stained in DNA-free water for
30 min while the other gel was stained in an ethidium bromide/buffer solution for 30 min. It
was then de-stained as mentioned before. The bands on the gel were imaged under UV light
using a GEL Logic 440 Imaging System with Kodak Molecular Imaging Software.
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2.6 Reaction with human serum albumin (HSA)
2.6.1 Fluorescence titration—For the fluorescence titration, a similar procedure to the
EB displacement experiments was done. Solutions of HSA (fatty acid-free) were prepared in
TRIS buffer (50 mM TRIS, pH 7.40, 100 mM NaCl) and stored in the dark at 4 °C. The
protein concentration was determined spectrophotometrically using the molar absorptivity of
3.6 × 104 M−1 cm−1 at 280 nm [24]. In the experiments, a 3.0 mL solution of HSA (5 µM)
was placed in a quartz cuvette and titrated with various amounts of a concentrated solution
of the complex producing the solutions with varied mole ratios of complex to HSA. The
complex concentration ranged from 3 to 30 µM. The fluorescence spectra of the solutions
were obtained by exciting at 295 nm and measuring the emission spectra from 300 – 500
nm.
2.6.2 Infrared spectrophotometry—IR spectra in the range 1200 to 2000 cm−1 were
obtained using the ATR accessory (with a germanium crystal) on a Nicolet 6700 FTIR
spectrophotometer equipped with a DTGS KBr detector and a KBr beam splitter. The
infrared spectra of HSA, HSA plus the complex (1:1 molar ratio) and the complex alone
were recorded. The HSA-complex solutions were incubated for 24 h prior to measurement.
The absorbance of the buffer was subtracted from the spectra of the solutions. Then
difference spectra were calculated using the instrument’s software package.
2.7 Cell culture
Cell lines included two human colon cancer cells: HCT116 (human colon carcinoma) and
Caco-2 (human epithelial colorectal adenocarcinoma). In addition, normal human colon
cells CCD-18Co (human colon fibroblasts), were included. All cell lines were obtained from
the American Type Culture Collection (ATCC, Rockville, MD, USA) and maintained at the
University of Rhode Island. Caco-2 cells were grown in EMEM medium supplemented with
10% v/v foetal bovine serum, 1% v/v nonessential amino acids, 1% v/v L-glutamine and 1%
v/v antibiotic solution (Sigma). HCT-116 cells were grown in McCoy’s 5a medium
supplemented with 10% v/v foetal bovine serum, 1% v/v nonessential amino acids, 2% v/v
HEPES and 1% v/v antibiotic solution. CCD-18Co cells were grown in EMEM medium
supplemented with 10% v/v foetal bovine serum, 1% v/v nonessential amino acids, 1% v/v
L-glutamine and 1% v/v antibiotic solution and were used from PDL = 26 to PDL = 35 for
all experiments. Cells were maintained at 37 °C in an incubator under a 5% CO2/95% air
atmosphere at constant humidity and maintained in the linear phase of growth. The pH of
the culture medium was determined using pH indicator paper (pHydrion™ Brilliant, pH 5.5–
9.0, Micro Essential Laboratory, NY, USA) inside the incubator. All of the test samples
were solubilized in DMSO (<0.5 % in the culture medium) by sonication and were filter
sterilized (0.2 µm) prior to addition to the culture media. Control cells were also run in
parallel and subjected to the same changes in medium with a 0.5 % DMSO.
2.7.1 Cytotoxicity assay—The assay was carried out as described previously [25] to
measure the IC50 values for samples. Briefly, the in vitro cytotoxicity of samples were
assessed in tumour cells by a tetrazolium-based colorimetric assay, which takes advantage of
the metabolic conversion of MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfenyl)-2H–tetrazolium, inner salt] to a reduced form that
absorbs light at 490 nm. Cells were counted using a haemocytometer and were plated at
2,000 to 5,000 cells per well, depending on the cell line, in a 96-well format for 24 h prior to
drug addition. Test samples and a positive control, etoposide 4 mg/mL (Sigma), were
solubilized in DMSO by sonication. All samples were diluted with media to the desired
treatment concentration and the final DMSO concentration per well did not exceed 0.5%.
Control wells were also included on all plates. Following a 24 h, 48 h or 72 h drug-
incubation period at 37 °C with serially diluted test compounds, MTS, in combination with
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the electron coupling agent, phenazine methosulfate, was added to the wells and cells were
incubated at 37°C in a humidified incubator for 3 h. Absorbance at 490 nm (OD490) was
monitored with a spectrophotometer (SpectraMax M2, Molecular Devices Corp., operated
by SoftmaxPro v.4.6 software, Sunnyvale, CA, USA) to obtain the number of surviving cells
relative to control populations. The results are expressed as the median cytotoxic
concentrations (IC50 values) and were calculated from six-point dose response curves using
4-fold serial dilutions. Each point on the curve was tested in triplicate. Data are expressed as
mean ± SE for three replicates on each cell line.
2.8 Antimicrobial assay
The in vitro antimicrobial activity of the ligands and 3 and 4 was investigated as the
minimum inhibitory concentration (MIC) against a number of Gram positive
(Staphylococcus aureus, Bacillus cereus, Enterococcus faecalis) and Gram negative
(Escherichia coli, Pseudomonas aeruginosa, Salmonella typhimurium bacteria strains. The
bacteria were maintained on nutrient agar and cultured in Mueller Hinton Broth and
compounds were dissolved in DMSO. The MIC was determined from a microdilution
method. Approximately 30-mL of bacteria culture was incubated overnight at 37.0 °C to
produce exponentially growing cells. This was then diluted to yield a suspension containing
1.5 × 108 CFU/mL (based on comparison of the turbidity to a 0.5 McFarland standard).
Subsequently, 250 µL of this bacteria mixture were then inoculated into a sterile 96-well
microplate. Various amounts of the compounds were added to wells to give predetermined
concentrations ranging from 2 to 50 µM. The well absorbances (at 600 nm) were recorded
on a BioTek Synergy HT microplate reader immediately after inoculation. The microplates
were incubated for 24 h at 37.0 °C, and then the absorbance recorded again after the 24 h.
The MIC was defined as the lowest concentration of compound that did not produce any
visible cell-growth or change in absorbance after incubation. Solvent, media and positive
growth controls were included on each plate. Ampicillin or streptomycin was used as a
standard comparison. Each plate contained three replicates of each concentration and two
separate experiments were done.
3 Results and Discussion
3.1 Synthesis and Characterization
The thiosemicarbazones used in this study are shown in Fig. 2. They were synthesized by
the acid-catalyzed condensation of piperonal with the appropriately substituted N-alkyl
thiosemicarbazide in ethanol. The complexes (1–4) were synthesized from [Ru(p-
cymene)Cl2]2 by reaction with two equivalents of the thiosemicarbazone in CH2Cl2 at room
temperature under argon. The yellow-orange solids that were obtained were very soluble in
DMSO but less so in alcohols. Based on elemental analysis and spectroscopic data we
propose that the complexes are best formulated as [(η6-p- cymene)Ru(TSC)Cl]Cl (Fig. 2).
Although the analysis results for “H” (1) are somewhat unsatisfactory, the spectroscopic
data (IR, 1H and 13C NMR) reasonably support the formula of the compound. [The
complexes with pHTSC (1) and pMeTSC (2) as ligands were very difficult to handle.
Detailed experiments were not performed using these complexes].
Thiosemicarbazone ligands can coordinate in a number of different ways. Most commonly
they bind as either of two tautomeric forms - a neutral thione form or the anion from the
thiol form. Infrared spectrophotometry was used to confirm coordination as the thione form.
The ligands and complexes are very soluble in DMSO and so their NMR spectra were
obtained in DMSO-d6. The 1H NMR spectra of the ligands show similar patterns for the
benzodioxole moiety differing only in the signals associated with the Nb-R group. The Na-H
resonates as a sharp singlet at 11.32 – 11.38 ppm (11.74 ppm for pPhTSC). For this ligand
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as well the NbH proton is at 10.11 ppm compared to 7.94 – 8.04 ppm observed for the
others. This shift downfield is possibly due to the proton locating in the cone of the phenyl
ring or more likely to the electron density redistribution in the skeleton of the molecule. For
pHTSC, the NbH2 group generates two distinct singlets at 8.01 and 8.04 ppm. This pattern is
to be expected as the protons are magnetically non-equivalent as a consequence of the C9-Nb
bond possessing some π character via the mesomeric effect. This results in hindered rotation
about this bond which is common in thioamides. The protons of the dioxole moiety show at
6.07 ppm. All the other protons resonate in regions commonly expected. In all cases for the
ligands the absence of a signal at ~4.00 ppm that can be ascribed to –SH [26] is consistent
with the idea that in solution, as in the solid state, the ligands exists as the thione tautomer.
The 13C NMR spectra for the ligands are exactly as would be expected. Of special note is
the high frequency signal near 180 ppm which is due to the thioamide carbon, C9. There
appears to be a general up-field shift of this resonance (in roughly 1 ppm increments) as the
Nb-R group changes from H → CH3 → C2H5 →C6H5. This might suggest that the R is
affecting the electronic nature of the thioamide bond.
The 1H NMR and 13C NMR spectra of the complexes are essentially a direct combination of
the signals from the ligands plus those from the p-cymene moiety. In the 1H NMR spectra
all indications are that the ligands remain neutral (as evidenced by the presence of the Na-H
protons). None of the major indicator peaks of the ligands move significantly on
complexation. The Na-H signal along with the Nb-H and C8-H signal shift only slightly (~ ±
0.03 ppm). The signals for the benzodioxole protons are just as unaffected by complexation.
The p-cymene protons resonate at frequencies typically seen for this group [26]. A multiplet
is seen near 5.80 ppm attributed to the ring protons; the isopropyl methine is found near 2.80
ppm with the methyls occurring as a doublet at 1.20 ppm. The signal due to the methyl on
the ring is observed at 2.10 ppm. A similar situation is observed from the 13C spectra. The
signals in the complexes attributed to the ligand are practically unchanged from the free
ligands. This is somewhat unexpected especially for the C9-S and C8-N signals since they
bind to the metal centre and changes in the electron density of these bonds might be
expected.
The redox behaviour of complexes 3 and 4 has been studied by cyclic voltammetry in the
positive region at a platinum disc electrode in 1.0 mM solutions in dichloromethane
containing 0.1 M tetrabutylammonium hexafluorophosphate as the supporting electrolyte.
Both complexes show two consecutive irreversible oxidations; the first at + 0.683 V for 3
and + 0.680 V for 4, corresponding to the Ru(II)/Ru(III) couple. The second is an ill-defined
oxidation wave at higher potential (near 1600 mV vs. Ag/AgCl) that becomes slightly less
defined as the scan rate is increased. Still the Ru-centred oxidation is irreversible even up to
a scan rate of 500 mV s−1 (see Supplemental Information - Fig. S1).
The structure of 4 has been confirmed by X-ray methods. The crystal structure of [(η6-
(cymene)Ru(pPhTSC)Cl]+ is shown in Fig. 3. The crystallographic data, description and
selected bond lengths and angles are given in Tables 1 and 2. The complex adopts the
archetypical piano-stool shape of Ru half-sandwich arene complexes. The metal centre has a
slightly distorted octahedral geometry with bite angles around the ruthenium, involving the
three legs of the piano stool, in the range 82° – 87°. This level of distortion is less than that
seen in other structurally characterized Ru-arene thiosemicarbazone complexes [12]. The
Ru-Cl bond length of 2.4100(6) Å is in the same range as for similar complexes [12, 28]
including those containing a π-acid with a nitrogen donor group [28]. The Ru-N(3),
2.1306(17) Å, and Ru-S(1), 2.3492(6) Å, along with the Ru-arene centroid distance of 1.699
Å are also essentially the same as we have observed for other Ru-arene thiosemicarbazone
complexes [12]. As seen in those other complexes as well, the arene ring is oriented so as to
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possibly limit any steric interaction between the isopropyl group and the sulphur of the
thiosemicarbazone ligand. The C(9)-S(1) bond-length of 1.697(7) and the C(8)-N(1) bond-
length of 1.288(5) Å are typical of the C=S and C=N bonds found in free
thiosemicarbazones and coordination complexes where the thione formed is coordinated,
that we found trawling the literature.
3.2 Interaction with DNA
The mechanism of the biological action of half-sandwich Ru-arene complexes,
[(arene)Ru(LL)Cl]+, is being intensively studied [3,4]. It is believed that aquation of this
complex generates a more reactive species towards DNA [29]. This binding may be
facilitated by hydrophobic interactions with the arene while the ligand provides an
additional site for binding. It has been established [3] that more hydrophobic arenes such as
5,8,9,10-tetrahydroanthracene and 9,10-dihydroanthracene (DHA) are stronger binders to
DNA and are more cytotoxic compared to p-cymene. As it relates to the chelating ligand the
structure-activity relationships for these complexes is somewhat complex. It was originally
believed that a NH on the chelating ligand was required (based on the parent
ethylenediamine complex for this class of compounds), but complexes with other ligands
such as acetylacetonate (acac) or the monodentate phosphine 1,3,5-triaza-7-
phosphaadamantane (pta) [4] have shown good activity. Also when ethylenediamine is
replaced by acac as the ligand the complex with p-cymene is more cytotoxic than that with
the DHA [3]. It is also known that the ligand will also affect hydrolysis rates of the
complexes. The design of our complexes was to facilitate this bifunctional mode of action
that may include covalent binding to the nucleobases and non-covalent interactions such as
groove binding or intercalation through the thiosemicarbazone ligand. The ligand has the
piperonal moiety which contains the dioxole oxygens as well as NH groups that may
participate in hydrogen bonding interactions with the DNA. We have studied the aquation
reaction of 3 and 4. Concentrated solutions of the complexes in DMSO were diluted in
aqueous buffer to a final concentration of 10 µM. The samples were analyzed by UV-Vis
spectrophotometry, monitoring the absorbance changes of a broad band centred near 345 nm
over 2 h at 298 K (see Fig. S2). This absorption of this band shifts to 332 nm and decreased
as the reaction progressed. Further evolution of the spectrum over 24 h showed an increase
in absorbance (no wavelength change) after 3h but the spectrum after 24 h was not
significantly different in shape and position form the spectrum after 2 h. For compound 4 the
band red shifts to about 354 nm. The hydrolysis constant for 3 was calculated to be (1.4 ±
0.3) × 10−3 s−1 and (6.6 ± 1.8) × 10−4 s−1 for 4. By comparison for a similar compound,
[(η6-p-cymene)Ru(9-anthraldehyde-N(4)-ethylthiosemicarbazone)Cl]+, we calculated the
rate of aquation to be (1.2 ± 0.2) × 10−3 s−1 at an ionic strength of 50 mM NaCl at 298 K. In
addition other structurally similar complexes, [(η6- p -X)Ru(en)Cl][PF6], where X =
biphenyl, 5,8,9,10-tetrahydroanthracene, and 9,10-dihydroanthracene and en =
ethylenediamine, have been reported to have aquation rates of 1.23 – 2.59 × 10−3 s−1 at 298
K and 100 mM ionic strength [30]. While the exact nature of the hydrolysis product is
unknown (as the kinetic traces indicate further transformation after about 2½ h), it is
reasonable to propose that the complexes possess the ability to aquate and bind DNA via a
covalent bond. Further studies using model nucleobases may illuminate this issue.
3.2.1 Ethidium bromide competition experiments—To investigate other possible
modes of binding with DNA, we have carried out a competition experiment with EB. The
complexes do not show any appreciable emission in DMSO and also lack emission in buffer
even in the presence of DNA. The experiment with EB is based on the ability of the metal
complex to quench, even partially, the fluorescence of the complex formed between the EB
and DNA. EB is a known intercalator into DNA and reduction of the fluorescence of this
complex in the presence of the metal complexes may be interpreted as being due to
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replacement of some of the EB molecules by the complexes. Implicit here is the idea that the
complexes may intercalate into DNA. It is also true however that the reduction in
fluorescence may be due to a direct quenching on the DNA itself. Figure 4 and Figure 5
show the moderate decrease (~ 35%) in fluorescence when EB-DNA is titrated with 3 and 4.
The extent of the fluorescence quenching can be used to determine the extent of the
interaction with the complexes.
In order to quantitatively assess the magnitude of this interaction between the complexes and
DNA, the Stern-Volmer equation is used:
(1)
F and F0 are the fluorescence intensities of the DNA solution in the presence and absence of
the complexes, KSV is the Stern-Volmer quenching constant and [Ru] is the concentration of
the metal complexes. The insets of Fig. 4 and Fig. 5 are the Stern-Volmer plots and the good
linearity of the plots suggests a singular mode of quenching. The values for the KSV are
given in Table 3. These values are on the order of 103 to 104 M−1 which makes the
complexes weak intercalators. The apparent binding constant for complexes was calculated
using the equation: Kapp = KEB[EB]/[Ru]50% where KEB = 1.2 × 106 M−1 [31]. KEB is the
binding constant of EB to DNA and [Ru]50% is the concentration of 3 and 4 at 50% of the
initial fluorescence. These Kapp values are also given in Table 3 and are on the same order of
magnitude as the KSV values.
We carried out a similar competition experiment using Hoechst 33258. This dye binds to B-
DNA in two concentration dependent ways. The first type of binding occurs in the minor
groove at low dye-to-DNA ratios [32,33]. The fluorescence yield of Hoechst 33258
increases significantly in presence of DNA [34]. The displacement of bound Hoechst 33258
from its binding site on ct-DNA is implicated from a decrease in its fluorescence intensity
on addition of the complexes. When the complexes are added to Hoechst-DNA solution we
observed a decrease (34% for 3 and 50% for 4) in the fluorescence (see Fig. S3 and S4).
This suggests that the complexes are capable of binding in the minor groove of DNA.
3.2.2 Viscometric studies—Among the most common methods used to investigate the
possibility of an intercalative mechanism, hydrodynamic measurements (viscometry in
particular) that are sensitive to DNA length changes are the most definitive. A classical
intercalator will cause an increase in the viscosity of a DNA solution since the DNA helix
must lengthen as base pairs are separated to accommodate the binding ligand [35]. On the
other hand, complexes that bind exclusively in the DNA grooves by a partial or non-
classical intercalation of the compound, (under the same conditions), can reduce its effective
length, and concomitantly, its viscosity by bending the DNA helix [36]. The viscometric
experiments involve measuring the viscosity of ct-DNA solutions (100 µM) containing
various amounts of 3 or 4 (0 – 60 µM). The data were treated by plotting (η/η0)1/3 vs. the
binding ratio [Ru]/[DNA]. (See Fig. S5). It was observed that increasing the concentration
of 3 or 4 led to an increase in the viscosity of the DNA solution followed by a decrease at
higher concentrations. From this figure we can suggest that the interaction with DNA is
somewhat non-specific and the complexes are weak intercalators.
3.2.3 Cleavage of plasmid DNA—The chemical nuclease activity of complexes 3 and 4
has been assessed by their ability to convert supercoiled pBR322 DNA from Form I to Form
II by agarose gel electrophoresis in the dark as well as under UV irradiation under aerobic
conditions. When circular plasmid DNA is probed by electrophoresis, relatively fast
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migration is normally observed for the intact supercoil form (Form I). If scission occurs on
one strand (nicking), the supercoil will relax to generate a slower-moving open circular form
(Form II). In the dark or following irradiation with UV light the complexes show no
significant cleavage of the DNA but there is a slight increase in this activity as the
concentration of the complexes increased (up to 300 uM) (see Fig. S6). We also studied the
reaction in the presence of hydroxyl scavengers HCOONa and KI as well as the singlet
oxygen-like species scavenger NaN3. These species seem capable of inhibiting the marginal
nuclease activity of the complexes with sodium azide appearing to be the strongest inhibitor.
This would seem to imply the role of reactive-oxygen species in the interaction of the
complexes with DNA.
3.3 Topoisomerase inhibition
Topoisomerases are a class of ubiquitous enzymes that modulate the topological problems
associated with DNA replication, transcription, and other nuclear processes by introducing
transient single- (type I topoisomerase) or double-strand (type II topoisomerase) breaks in
the DNA. Without topoisomerases, the DNA cannot replicate normally and topo II is a
major enzyme in neoplastic cells. So although DNA is implicated as the main target for
anticancer ruthenium compounds, affecting the activity of topo II may also be an effective
mode of antineoplastic activity. Topoisomerase inhibitors are substances that interfere with
the normal functioning of topoisomerase enzymes. These inhibitors are split into two main
classes: topoisomerase poisons, which target the topoisomerase-DNA complex, and
topoisomerase inhibitors which disrupt the enzyme’s catalytic cycle. The ability of
complexes 3 and 4 to affect the catalytic activity of human topoisomerases II was studied by
a DNA relaxation assay. Supercoiled plasmid DNA was treated with topo II in the presence
of varying concentrations of the complexes and the products were analysed by agarose gel
electrophoresis. Depending on the nature of the products one can propose if the complex is a
poison or an inhibitor. Fig. 6 shows the gel electrophoretic diagram for the concentration-
dependent experiment. Enzyme activity is characterized by conversion of pHOT1 DNA
from the supercoiled conformation (I) to the fully relaxed conformation (II). The species
migrating between the two forms (lane 3) are the various topoisomers indicating that the
enzyme was causing relaxation. From the figure it is clear that both complexes can prevent
the relaxation by the enzyme (to almost the same extent) at concentrations as low as 20 µM
(lanes 4–7) as evidenced by the absence of the topoisomers and the presence of mainly the
supercoiled form of the DNA. So we propose that the complexes can act as strong catalytic
inhibitors. There was no formation of linear DNA, which would be evidence for the
formation of an enzyme-drug-DNA ternary complex, during the reaction which supports the
preceding conclusion. Previously, moderate to strong anti-topoisomerase activity by arene-
ruthenium complexes of the type [(benzene)Ru(DMSO)Cl2] and [(benzene)Ru(L)Cl2] (L =
pyridine, 3-aminopyridine, p-aminobenzoic acid, and aminoguanidine) was reported [37,
38]. Those complexes were observed to inhibit relaxation as well as promote formation of
the cleavage complex or cross-linking with topoisomerase. We have also notice in our
research that complexes like 3 and 4 ([(cymene)Ru(TSC)Cl]+), can inhibit topo II to varying
degrees (F. Beckford, V. Crowell, P.C. Mbarushimana, unpublished work).
3.4 Interaction with human serum albumin
3.4.1 Fluorescence titration—As the principal extracellular protein of the circulatory
system, HSA serves as the major transporter of drugs as well as endogenous compounds
such as fatty acids since these compounds can bind reversibly to the HSA. It has been shown
that the distribution, free concentration and the metabolism of various drugs can be
significantly altered as a result of their binding to HSA. HSA also often increases the
apparent solubility of hydrophobic drugs in plasma. Since HSA serves as a transport carrier
for drugs, it is important to study the interactions of potential drugs with this protein.
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Knowledge of interaction mechanisms between drugs and plasma proteins is of crucial
importance to the understanding of the pharmacodynamics and pharmacokinetics of a drug
or drug prospect. Fluorescence spectrophotometry is a powerful method to study molecular
interaction with proteins. We have studied the interaction of 3 and 4 with HSA by emission-
quenching experiments. HSA contains 585 amino acid residues with a single tryptophan
located at position 214. Tryptophan fluorescence is the most frequently studied among the
three fluorescent groups in HSA. By measuring the intrinsic fluorescence quenching of
HSA, the accessibility of quenchers to the tryptophan residue can be estimated. When HSA
is excited at 295 nm, changes in a fluorescence emission near 350 nm reflect modification in
the micro-environment of the tryptophan residue. It can be observed from Fig. 7 and Fig. 8
that titration of HSA with the metal complexes led to dramatic decreases in the HSA
fluorescence (80% of the initial fluorescence for 3 and 90% for 4) suggesting that binding
occurs at or near the tryptophan residue causing changes in the secondary structure of the
protein. It can also be observed that there is a blue shift of about 17 nm to near 330 nm. It
seems likely that binding results in reduction of the tryptophan exposure to a polar
environment. Emission in this region suggests that the tryptophan residue is buried in a
nonpolar hydrophobic pocket on the HSA.
The insets of Fig. 7 and Fig. 8 shows the Stern-Volmer plot which is expected to be a
straight line. However it is obvious that there are strong positive deviations in the plots. The
concave-up nature of these plots usually indicates that both dynamic and static quenching is
involved. Under these circumstances the Stern-Volmer equation may be written as equation
2 [39].
(2)
A plot of Kapp vs. [Ru] should give a linear plot with (KS + KD) as the intercept and KDKS
as the slope. KS and KD are the quenching contributions from the static and dynamic
mechanisms respectively. In our analysis we were unable to separate the two contributions
as imaginary numbers resulted from solving the equation. [Another way to estimate
qualitatively the type of mechanism present is to consider the effect of temperature on the
system]. We can therefore assume that both mechanisms play a significant role in the
quenching. Under these circumstances the fluorescence data may be treated with a modified
version of the Stern-Volmer equation:
(3)
This allows estimation of the apparent binding constant K for the process from the ratio of
the slope to intercept of a plot of F0/F vs. 1/[Ru]. (See Fig. S7). This plot is given in Figure
11. The calculated binding constants (Table 4) show that complex 4 interact stronger than 3,
105 vs. 104 M−1. The thermodynamic parameters (ΔH and ΔS) derived from the van’t Hoff
equation are also given in Table 4 and may be used to suggest the binding mode. The
various forces of attraction between the complexes and the HSA include hydrogen bond
formation, electrostatic forces, van der Waals forces and hydrophobic interactions.
According to Ross and Subramanian [40] when ΔH > 0 and ΔS > 0, the situation observed in
our cases, hydrophobic interactions are implicated as the major binding mode. We can infer
from the small positive ΔH of 5.43 kJ/mol for 4 that electrostatic binding also plays a part.
Typically for electrostatic interactions ΔH is zero or a small positive value [40]. This might
explain the much higher binding constants for this complex. There is not much literature
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precedent for complexes like 3 and 4 interacting with HSA, but it is possible that covalent
binding to the ruthenium center does occur. It is known that DNA binds very strongly
(through a guanine residue) to such complexes with the aid of hydrophobic forces [41]. A
similar reaction with HSA through the indole ring on the tryptophan would be weak
however as it would require deprotonation of the indole nitrogen. By analogy with the
purine bases of DNA, this is less probable under physiological pHs. Still, with the data at
hand it is not clear that we can quantitatively separate out the contribution of any covalent
interaction. Nonetheless this idea is part of the design strategy of this class of anticancer
compounds: the incorporation of features that enhance simultaneous hydrophobic and
covalent coordination in order to optimize biological targeting. The binding process is
always spontaneous as implied by the negative value of ΔG°. It can also be suggested that
the entropic term provides the major contribution to the free energy.
3.4.2 Infrared spectrophotometry—The infrared spectra of proteins exhibit the amide I
bond (due to the stretching of the C=O functional group of the peptide moiety) between
1600 and 1700 cm−1. The exact position is determined by the backbone conformation. Since
this band is associated with the secondary structure of the protein [42] perturbations of the
bond on interaction with the metal compounds can provide a qualitative assessment of the
binding assuming that the binding induces a conformation change. Infrared spectroanalysis
of a solution of HSA before and after incubation with 3 and 4, show that the amide I band
shift only slightly ′ 1638.23 to 1638.72 cm−1 for 3 and 1638.73 to 1639.68 cm−1 for 4 (see
Fig. S8). Though other reasons are possible, this indicates that the secondary structure of
HSA is perturbed though not dramatically so. It also confirms that 4 interact stronger with
HSA.
3.5 Biological Activity
3.5.1 Cytotoxicity assay—The in vitro cytotoxicity of complexes 3 and 4 against two
human cancer cell lines, HCT-116 (colon carcinoma) and Caco-2 (epithelial colorectal
adenocarcinoma) and a non-cancerous cell line, CCD-18Co (colon fibroblasts) was
investigated using a tetrazolium-based (MTS) colorimetric assay. Etoposide, a potent anti-
neoplastic drug, and cisplatin, a platinum-based chemotherapy drug, were used as a standard
comparison treatment. The IC50 values, the median cytotoxic concentrations, were
determined after 24, 48 and 72 h of drug exposure. Generally, the longer the exposure time
the more cytotoxic is the complexes with the 72 h exposure being between 1.3 and 2 times
more effective compared to the 24 h exposure. As another generality, the Caco-2 cell line is
more sensitive to the complexes than the HCT-116 cell line. For instance at 72 h exposure, 3
is twice as cytotoxic against the Caco-2 line. Furthermore 3 is more active than 4 against
Caco-2 and HCT-116 (IC50 = 26.3 to 121 and 50.5 to 153 µM, respectively), Table 5).
Given that 4 has a stronger binding to DNA, we speculate that DNA interaction may not be
the primary reason for the cytotoxic behaviour. From a simple structure-activity analysis
(see Table S1) we can also speculate that the alkyl group on the thiosemicarbazone moiety is
probably non-innocent as there are distinct differences in the cytotoxic behaviour as that
group is varied.
As a point of interest, it was observed that the cytotoxic effect on the non-cancerous cell line
is noticeably less than on the two cancer lines. The small effect is true even for the standard
drug treatment with etoposide being about ~2.5 times more lethal to the cancer cells versus
the non-cancerous cells. The IC50 values for the complexes are in the micromolar range
indicating the good to moderate cytotoxicity of the complexes, being about ~2.5 and ~1.3
times as active against HCT-116 and HT-29, respectively (Table 5). Finally, under the
experimental conditions 3 shows comparable activity to etoposide and cisplatin (26.3 µM to
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16.5 µM and 14.9 µM, respectively) against Caco-2. On the other hand, IC50 values after
treatment with 4 show higher differences (Table 5).
In general however the complexes do not reach the activity of the standard against the
cancer cell lines. This is in itself not an unusual issue. It is known that some ruthenium arene
complexes have low in vitro toxicity but show good in vivo anti-metastatic characteristics.
For example, complexes of the type [(η6-cymene)Ru(PTA)Cl]+ exhibited low activity
against cancer cells but had very good antimetastatic activity in vivo [4].
3.5.2 Antimicrobial Studies—The in vitro antimicrobial efficiency of the ligands and the
complexes 3 and 4 against a number of Gram-positive and Gram-negative bacteria has been
determined as the minimum inhibitory concentrations (see Table S2). The compounds were
tested at low concentrations due to solubility issues and to avoid excessive concentrations of
the solvent DMSO in the wells. The complexes were more active against the Gram-positive
bacteria than the Gram-negative species showing moderate activity against Bacillus cereus
and Staphylococcus aureus. In general 4 is more active than 3 for bacteria for which an IC50
value was determined. For instance the IC50 for 4 against Staphylococcus aureus is 30 µM
and for 3 it was 50 µM. The complexes were also found to be more active than the free
ligand. This is not unusual because as mentioned before it is known that complexation to a
metal ion may induce improved biological activity and in some cases even different
biological activity [16–18, 43]. Such complexation could enhance the lipophilic character of
the compound which favours its permeation through the lipid layers of cell membrane.
Although the complex is active, at least against certain species, it typically did not achieve
the effectiveness of the conventional antibacterial standards ampicillin or streptomycin.
4. Conclusions
We have prepared a series of new ruthenium-arene piano-stool complexes with
thiosemicarbazones as the coordinating ligand. The compounds show in vitro activity as
anticancer agents against human colon cancer cells. DNA has been postulated as a primary
target for organometallic ruthenium anticancer compounds and the studied compounds
interact with moderately with DNA though we cannot conclusively say in what manner.
They can also inhibit the activity of human topo II and it is clear that this enzyme may
therefore be an important target for these types of compounds. With respect to the modest
anticancer behaviour, the compounds are not dissimilar from other ruthenium arene
complexes under active investigation and these complexes may still have the potential for
drug development.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Abbreviations
HSA human serum albumin
TSC thiosemicarbazone
CFU colony forming units
EMEM Eagles minimum essential medium
Topo II topoisomerase II
PDL population double level
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EB ethidium bromide
SERM selective estrogen receptor modulators
ER estrogen receptor
MSV modified Stern-Volmer
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Figure 1.
Antitumor organometallic complexes
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Figure 2.
Structure of the ligands (including a labeling scheme) and complexes used in this study
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Figure 3.
An OPTEP drawing at 50% thermal ellipsoids probability. A perspective view of the
molecular structure and numbering scheme for the [η6p -cymene)Ru(pPhTSC)Cl]+ cation
(4). The label for hydrogen atoms, the chloride counter-anion and disordered molecule of
dichloromethane are not shown for clarity.
Beckford et al. Page 20
J Inorg Biochem. Author manuscript; available in PMC 2012 August 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4.
Fluorescence spectra of EB-bound ct-DNA in aqueous buffer in the presence of increasing
amounts of 3, at 303 K. λex= 520 nm, [EB] and [DNA] are 0.33 µM and 10 µM respectively.
[3] = (a) 0 µM, (b) 10 µM, (c) 10 µM, (d) 15 µM, (e) 20 µM, (f) 25 µM, (g) 30 µM, (h) 35
µM, (i) 40 µM, (j) 45 µM, (k) 50 µM, (l) 55 µM, (m) 60 µM. Inset: Stern-Volmer plots
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Figure 5.
Fluorescence spectra of EB-bound ct-DNA in aqueous buffer in the presence of increasing
amounts of 4, at 303 K. λex= 520 nm, [EB] and [DNA] are 0.33 µM and 10 µM respectively.
[4] = (a) 0 µM, (b) 2.5 µM, (c) 5.0 µM, (d) 7.5 µM, (e) 10 µM, (f) 12.5 µM, (g) 15 µM, (h)
17.5 µM, (i) 20 µM, (j) 22.5 µM, (k) 25 µM, (l) 27.5 µM, (m) 30 µM (n) 32.5 µM, (o) 35
µM, (p) 37.5 µM, (q) 40 µM . Inset: Stern-Volmer plots
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Figure 6.
Gel electrophoresis diagram for the interaction of 3 (A) and 4 (B) with human
topoisomerase II. (A) Lane 1: DNA (pHOT1 – 12.5 ng/µL); Lane 2: DNA & Enzyme; Lane
3: DNA, Enzyme & DMSO; Lanes 4,5, 8: Ru concentrations 20, 30, 100 µM; Lane 6:
Linear DNA Marker Lane 7: etoposide; (B) Lane 1: DNA (pHOT1 – 12.5 ng/µL); Lane 2:
DNA & Enzyme; Lane 3: DNA, Enzyme & DMSO; Lanes 4–7: Ru concentrations 20, 30,
50, 100 µM; Lane 8: etoposide; Lane 9: Linear DNA Marker
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Figure 7.
Emission spectra of the HSA in the presence of increasing amounts of 3, λex= 295 nm,
[HSA] = 5.0 µM and [3]: 0 – 35 µM (top-to-bottom in 2.5 µM increments). Temperature =
296 K. The inset is Stern-Volmer quenching plots.
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Figure 8.
Emission spectra of the HSA in the presence of increasing amounts of 4, λex= 295 nm,
[HSA] = 5.0 µM and [4]: 0 – 40 µM (top-to-bottom in 2.5 µM increments). Temperature =
296 K. The inset is Stern-Volmer quenching plots.
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Table 1
Selected crystallographic and refinement data for 4, [(η6p-cymene)Ru(pPhTSC)Cl]Cl
Parameter Value
Empirical formula C25H27Cl2N3O2RuS
Formula weight 605.53
T (K) 296(2) K
Wavelength (Å) 0.71073 Å
Crystal system Monoclinic
Space group P 21/n
Unit cell dimensions a = 14.9344(17) Å α = 90°.
b = 8.6668(10) Å β = 102.5730(10)°.
c = 20.910(2) Å γ = 90°.
Volume (Å3) 2641.5(5) Å3
Z 4
Densitycalc (Mg/m3) 1.523
Absorption coefficient (mm−1) 10.902 mm−1
Crystal size (mm3) 0.30 × 0.21 × 0.13 mm3
θ range 1.53 – 26.37°
Index ranges −18 ≤ h ≤ 18, −10 ≤ k ≤ 10, −26 ≤ l ≤ 26
No. reflections collected 27175
No. independent reflections 5704 [R(int) = 0.0280]
Absorption correction Numerical
Data/rest/param 5402 / 0 / 322
GOF F2 1.040
Final R indices; [I > 2σ(I)] R1 = 0.0252; wR2 = 0.0618
R indices (all data) R1 = 0.0330; wR2 = 0.0673
CCDC 798099
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Table 2
Selected bond lengths [Å] and angles [°] for 4, [(η6p-cymene)Ru(pPhTSC)Cl]Cl
Ru(1)-C(16) 2.213(2) Ru(1)-Cl(1) 2.4100(6)
Ru(1)-C(17) 2.166(2) Ru(1)-N(3) 2.1306(17)
Ru(1)-C(18) 2.169(2) Ru(1)-S(1) 2.34926(6)
Ru(1)-C(19) 2.270(2) N(1)-Ru(1)-S(1) 82.38(5)
Ru(1)-C(20) 2.239(2) N(1)-Ru(1)-Cl(1) 87.21(5)
Ru(1)-C(21) 2.174(2) S(1)-Ru(1)-Cl(1) 86.97(2)
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Table 3
Binding parameters for the interaction of 3 and 4 to the ct-DNA
3 4
Temperature (K) Kapp/103 (M−1) KSV/103 (M−1)
(R2)
Kapp/103 (M−1) KSV/103 (M−1)
(R2)
293 3.97 8.84
(0.995)
4.07 9.10
(0.992)
303 4.03 8.87
(0.998)
5.63 11.4
(0.997)
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